Adaptimmune Therapeutics Plc, a commercial-stage cell therapy company based in Abingdon, Oxfordshire, focuses on novel T-cell therapies for cancer, including afamitresgene autoleucel and Lete-cel. The company employs 449 people and went public on May 6, 2015.
Adaptimmune Therapeutics Plc (ADAP) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, Adaptimmune Therapeutics Plc's actual EPS was -$0.19, missing the estimate of -$0.15 per share, resulting in a -24.84% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
